Table 3 Study eligibility and exclusions
Duloxetine | Venlafaxine | SSRI | Untreated | |||||
|---|---|---|---|---|---|---|---|---|
N removed | N eligible remaining | N removed | N eligible remaining | N removed | N eligible remaining | N removed | N eligible remaining | |
Member of commercial health insurance plan, with medical coverage and pharmacy benefits, and presence of qualifying eventa during the accrual period | 156,682 (100.0 %) | 231,793 (100 %) | 1,314,147 (100 %) | 1,577,784 (100 %) | ||||
Baseline exclusions | ||||||||
Less than 18 years at index date | 1396 | 155,286 (99.1 %) | 2482 | 229,311 (98.9 %) | 33,476 | 1,280,671 (97.5 %) | 60,552 | 1,517,232 (96.2 %) |
Less than 12 months prior continuous enrollment | 79,819 | 75,467 (48.2 %) | 136,147 | 93,164 (40.2 %) | 780,943 | 499,728 (38.0 %) | 791,027 | 726,205 (46.0 %) |
Prior dispensing of study drug or drug class in the baseline | 0 | 75,467 (48.2 %) | 23,753 | 69,411 (29.9 %) | 134,294 | 365,434 (27.8 %) | 334,496 | 391,709 (24.8 %) |
Had no depression diagnosis in the baseline | 27,596 | 47,871 (30.6 %) | 24,844 | 44,567 (19.2 %) | 153,173 | 212,261 (16.2 %) | 0 | 391,709 (24.8 %) |
Had hepatic injury/chronic hepatic condition in the baseline | 10,592 | 37,279 (23.8 %) | 9173 | 35,394 (15.3 %) | 39,354 | 172,907 (13.2 %) | 76,815 | 314,894 (20.0 %) |
Region affected by Hurricane Katrina | 489 | 36,790 (23.5 %) | 509 | 34,885 (15.1 %) | 2020 | 170,887 (13.0 %) | 3556 | 311,338 (19.7 %) |
Cohort assignment based on earliest qualifying index date (pre-propensity score matching) | 30,844 (19.7 %) | 29,243 (12.6 %) | 166,236 (12.6 %) | 311,338 (19.7 %) | ||||